Completion

Great! This was
an amazing job!

Summarized here are the major recommendations for diagnostic evaluation of HER2-low IHC cases:

HER2 Diagnostik Übersicht

Modified according to Denkert C. et al., Die Pathologie 2022;43(6):457–66.

This tool has been developed by AstraZeneca and is for demonstration purposes, it is not meant to replace HER2 interpretation trainings.
The tool is intended for pathologists only.

Contact Us Legal notice Privacy Policy Cookie policy Report a possible side effect

×

You are now leaving AstraZeneca

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue